Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has provided an announcement.
On October 31, 2025, Smith & Nephew plc reported its total issued share capital, comprising 877,724,845 ordinary shares, with 29,017,524 held in treasury. This results in 848,707,321 shares with voting rights, a crucial figure for shareholders under the FCA’s Disclosure Guidance and Transparency Rules. This announcement ensures transparency and aids stakeholders in understanding their voting power and obligations.
The most recent analyst rating on (SNN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats’ strong financial performance and positive earnings call outlook are the primary drivers of its stock score. While technical indicators show mixed momentum, and valuation suggests the stock may be expensive, the company’s robust cash flow and strategic initiatives support a positive outlook. Challenges in emerging markets and potential tariff impacts are notable risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a leading company in the medical technology industry, specializing in advanced wound management, orthopedics, and sports medicine. The company focuses on providing innovative solutions to improve patient outcomes and enhance healthcare delivery worldwide.
Average Trading Volume: 737,128
Technical Sentiment Signal: Buy
Current Market Cap: $15.64B
For detailed information about SNN stock, go to TipRanks’ Stock Analysis page.